VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Objectively confirmed diagnosis of acute PE by     │ Objectively confirmed diagnosis of acute PE by     │     100 │
│ multidetector CT angiography,                      │ multidetector CT angiography,                      │         │
│ ventilation/perfusion lung scan, or selective      │ ventilation/perfusion lung scan, or selective      │         │
│ invasive pulmonary angiography, according to       │ invasive pulmonary angiography, according to       │         │
│ established diagnostic criteria, with or without   │ established diagnostic criteria, with or without   │         │
│ symptomatic deep vein thrombosis                   │ symptomatic deep vein thrombosis                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absence of hemodynamic collapse, or                │ Absence of hemodynamic collapse, or                │     100 │
│ decompensation, at presentation; Hemodynamic       │ decompensation, at presentation; Hemodynamic       │         │
│ collapse or decompensation                         │ collapse or decompensation                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At least one sign of RV pressure                   │ At least one sign of RV pressure                   │     100 │
│ overload/dysfunction on CT angiography or          │ overload/dysfunction on CT angiography or          │         │
│ echocardiography                                   │ echocardiography                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Signs of myocardial injury as indicated by         │ Signs of myocardial injury as indicated by         │     100 │
│ elevated troponin levels                           │ elevated troponin levels                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Ability of the subject to understand the character │ Ability of the subject to understand the character │     100 │
│ and individual consequences of the clinical trial; │ and individual consequences of the clinical trial; │         │
│ signed and dated informed consent of the subject   │ signed and dated informed consent of the subject   │         │
│ available before the start of any specific trial   │ available before the start of any specific trial   │         │
│ procedures                                         │ procedures                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy (a negative serum or urine pregnancy     │ Pregnancy (a negative serum or urine pregnancy     │     100 │
│ test should be available for women of child-       │ test should be available for women of child-       │         │
│ bearing potential before study inclusion) or       │ bearing potential before study inclusion) or       │         │
│ lactation                                          │ lactation                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Women of childbearing potential who do not         │ Women of childbearing potential who do not         │     100 │
│ practice a medically accepted highly effective     │ practice a medically accepted highly effective     │         │
│ contraception during the trial and one month       │ contraception during the trial and one month       │         │
│ beyond                                             │ beyond                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of hypersensitivity to the investigational │ History of hypersensitivity to the investigational │     100 │
│ medicinal product or to any drug with similar      │ medicinal product or to any drug with similar      │         │
│ chemical structure or to any excipient present in  │ chemical structure or to any excipient present in  │         │
│ the pharmaceutical form of the investigational     │ the pharmaceutical form of the investigational     │         │
│ medicinal product                                  │ medicinal product                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participation in another clinical trial during the │ Participation in another clinical trial during the │     100 │
│ present clinical trial or within the last three    │ present clinical trial or within the last three    │         │
│ months                                             │ months                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Medical or psychological condition that would not  │ Medical or psychological condition that would not  │     100 │
│ permit completion of the trial or signing of       │ permit completion of the trial or signing of       │         │
│ informed consent                                   │ informed consent                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of a fibrinolytic agent, surgical              │ Use of a fibrinolytic agent, surgical              │     100 │
│ thrombectomy, interventional (catheter-directed)   │ thrombectomy, interventional (catheter-directed)   │         │
│ thrombus aspiration or lysis, or use of a cava     │ thrombus aspiration or lysis, or use of a cava     │         │
│ filter to treat the index episode of PE            │ filter to treat the index episode of PE            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment with any therapeutically dosed           │ Treatment with any therapeutically dosed           │     100 │
│ anticoagulant for more than 48 hours prior to      │ anticoagulant for more than 48 hours prior to      │         │
│ enrolment                                          │ enrolment                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Need for long-term treatment with a low molecular  │ Need for long-term treatment with a low molecular  │     100 │
│ weight heparin, vitamin K antagonists or NOAC, for │ weight heparin, vitamin K antagonists or NOAC, for │         │
│ an indication other than the index PE episode, or  │ an indication other than the index PE episode, or  │         │
│ for antiplatelet agents except acetylsalicylic     │ for antiplatelet agents except acetylsalicylic     │         │
│ acid at a dosage ≤100 mg/day                       │ acid at a dosage =100 mg/day                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active bleeding or known significant bleeding risk │ Active bleeding or known significant bleeding risk │     100 │
│ (e.g., gastrointestinal ulcer, malignant           │ (e.g., gastrointestinal ulcer, malignant           │         │
│ neoplasms, injuries or recent surgeries of the     │ neoplasms, injuries or recent surgeries of the     │         │
│ brain, spinal cord or eyes, recent intracranial    │ brain, spinal cord or eyes, recent intracranial    │         │
│ bleedings, known or suspected esophagus varices,   │ bleedings, known or suspected esophagus varices,   │         │
│ aneurysms or intraspinal or intracranial vascular  │ aneurysms or intraspinal or intracranial vascular  │         │
│ abnormalities)                                     │ abnormalities)                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Artificial heart valves requiring treatment with   │ Artificial heart valves requiring treatment with   │     100 │
│ an anticoagulant                                   │ an anticoagulant                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Chronic liver disease with aminotransferase levels │ Chronic liver disease with aminotransferase levels │     100 │
│ two times or more above the local upper limit of   │ two times or more above the local upper limit of   │         │
│ normal range                                       │ normal range                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Concomitant administration of strong inhibitors of │ Concomitant administration of strong inhibitors of │     100 │
│ P-glycoprotein like ketoconazole, cyclosporin,     │ P-glycoprotein like ketoconazole, cyclosporin,     │         │
│ itraconazole or dronedarone                        │ itraconazole or dronedarone                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unwillingness or inability to adhere to treatment  │ Unwillingness or inability to adhere to treatment  │     100 │
│ or to the follow-up visits                         │ or to the follow-up visits                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Life expectancy less than 6 months                 │ Life expectancy less than 6 months                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age ≥18 years                                      │ Age =18 years                                      │      92 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Signs of (RV) failure as indicated by NT-proBNP    │ Signs of (RV) failure as indicated by NT-proBNP    │      99 │
│ levels \>600 pg/ml at baseline                     │ levels >600 pg/ml at baseline                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Renal insufficiency with estimated creatinine      │ Renal insufficiency with estimated creatinine      │      99 │
│ clearance \<30 ml/min/1.73m2                       │ clearance <30 ml/min/1.73m2                        │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒══════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                │ CHIA Criteria                                      │   Score │
╞══════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years                │ Age =18 years                                      │      43 │
├──────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intermediate-risk category of PE severity        │ History of hypersensitivity to the investigational │      44 │
│ indicated by a positive (score ≥1) simplified    │ medicinal product or to any drug with similar      │         │
│ pulmonary embolism severity index (sPESI), in    │ chemical structure or to any excipient present in  │         │
│ combination with the presence of at least one of │ the pharmaceutical form of the investigational     │         │
│ the following criteria at presentation           │ medicinal product                                  │         │
╘══════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 96
Average Levenshtein Ratio of individual lines: 94.875
OverAll Ratio: 95.4375
